



MyRightDose

Dose Exchange Program



Enrollment Form

- With MyRightDose, your patients can continue their Retevmo therapy at the appropriate dose for them, without the hassle of delays or additional co-pays

For more information, call 1-833-290-2175 Monday-Friday, 9 AM-6 PM ET, or visit [Retevmo.com](https://www.Retevmo.com).

Instructions for
Physician



Complete

Review and complete
this entire form



Sign

Prescriber must sign and date
the bottom of section 4



Fax

Fax this entire form to
1-844-372-9043

Eligibility Requirements

To be eligible for the MyRightDose program, a patient must:

- Return unused pills in the provided pre-addressed envelope and according to the instructions provided by MyRightDose
- Be 18 years of age or older (non-small cell lung cancer) or 12 years of age or older (thyroid cancer)
- Be a resident of the United States or Puerto Rico
- Be prescribed Retevmo for an FDA-approved indication

Please note: To provide their dose at no charge, this program is dispensed by Sonexus rather than your in-office dispensary or the specialty pharmacy that is currently dispensing your patient's prescription. Retevmo can be shipped to the patient as early as 48 hours after the receipt of this form. We will contact your office as soon as the patient's received their new dose so you can begin the process of starting their next month's script.

SECTION 1. PATIENT INFORMATION

Name	DOB (mm/dd/yyyy)	Phone
Address		
Email	Best time to contact	
Caregiver or authorized representative: Name		Phone

SECTION 2. PRESCRIBER INFORMATION

Name		Practice	
Address			
Office contact		Preferred method of contact: <input type="checkbox"/> Phone <input type="checkbox"/> Fax <input type="checkbox"/> Email	
Phone	Fax	Email	
NPI #	State license #	Tax ID #	DEA #

SECTION 3. PRESCRIPTION — Choose one in each column

Existing dose:

- ☐ Retevmo® (selpercatinib) 160 mg BID
- ☐ Retevmo® (selpercatinib) 120 mg BID
- ☐ Retevmo® (selpercatinib) 80 mg BID
- ☐ Retevmo® (selpercatinib) 40 mg BID
- ☐ Retevmo® (selpercatinib) 40 mg QD

New dose:

- ☐ Retevmo® (selpercatinib) 160 mg BID
- ☐ Retevmo® (selpercatinib) 120 mg BID
- ☐ Retevmo® (selpercatinib) 80 mg BID
- ☐ Retevmo® (selpercatinib) 40 mg BID
- ☐ Retevmo® (selpercatinib) 40 mg QD

Directions

Taken as
prescribed

Quantity

___ days to be exchanged

Diagnosis code

SECTION 4. TERMS AND CONDITIONS

- The MyRightDose program is available at no charge to a patient prescribed Retevmo for an FDA-approved indication for up to three separate dose exchanges in a 12-month period. The quantity to be exchanged should be between 5 and 30 days per exchange
- Neither the prescriber, prescriber's institution, pharmacy, pharmacist, or any other person, including the patient, may seek payment or accept reimbursement from any patient, any third-party payer, including any state or federal entity or any private or other insurance plan, or from any other person or entity, for Retevmo supplied under this program, regardless of whether the payer subsequently determines it will cover the product
- Product provided pursuant to this program may not be sold, traded, or distributed for sale
- If a patient is enrolled in a Medicare Part D plan, the prescriber must notify the patient that they must not attempt to have this prescription or any costs associated with it counted as any portion of true out-of-pocket ("TrOOP") cost for prescription drug calculations
- No purchase contingency or other obligation accompanies program participation
- Lilly reserves the right to change or end the program at any time without notice. Benefits provided under the program are not transferable

Prescriber: I certify that I understand and agree: 1) That I have explained to my patient that he/she must return the unused drug according to the instructions provided by the MyRightDose program; 2) To the Terms and Conditions of the MyRightDose program; 3) My patient meets the patient Eligibility Requirements of MyRightDose; 4) I am licensed to prescribe the prescription medication identified in this form, the prescription complies with my state-specific prescribing requirements; 5) In my medical judgment, the new strength of Retevmo is clinically appropriate for the patient named above and its use is consistent with the FDA-approved indication; and 6) This supply of Retevmo is specifically for the patient named above.

Prescriber's signature

Date

For assistance and/or additional information, call 1-833-290-2175 Monday-Friday, 9 AM-6 PM ET.

Please click to access full [Prescribing Information for Retevmo](#).

PP-SE-US-0496 12/2020. © Lilly USA, LLC 2020. All rights reserved.
Retevmo® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.